Current Status of BTKi Treatment for CLL/SLL in China

Current Status and Influencing Factors of Chinese Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Undergoing Treatment With Bruton's Tyrosine Kinase Inhibitors

BTKi has become the standard treatment regimen for CLL/SLL，there is a lack of large-scale real-world studies on the use status and related influencing factors of BTK inhibitors. Therefore, we plan to conduct this multicenter retrospective cross-sectional study to understand the current situation of BTK inhibitor treatment for CLL/SLL patients in China and the related influencing factors, and to explore more suitable treatment patterns based on this.

Inclusion Criteria:

• Age ≥ 18 years;
• Patients with a confirmed diagnosis of CLL/SLL;
• Received BTK inhibitor treatment between February 2023 and February 2024.

Exclusion Criteria:

• Patients with other types of lymphoma;
• Cases deemed unsuitable for inclusion in this study by the investigators.